Sekar P, Johnson W, George M, Breininger A, Parsons H, Vogel R
Support Care Cancer. 2025; 33(2):80.
PMID: 39870939
DOI: 10.1007/s00520-024-09132-8.
Jain S, Jain P, Puranik A
J Healthc Leadersh. 2024; 16:525-535.
PMID: 39679178
PMC: 11645248.
DOI: 10.2147/JHL.S486263.
Silva D, Nelson B, Rodon J
J Immunother Precis Oncol. 2024; 7(3):190-200.
PMID: 39219999
PMC: 11361338.
DOI: 10.36401/JIPO-23-33.
Misplon S, Marneffe W, Missiaen J, Myny D, Decock I, Lervant S
Arch Public Health. 2024; 82(1):95.
PMID: 38915071
PMC: 11194927.
DOI: 10.1186/s13690-024-01317-1.
Driller B, Talseth-Palmer B, Hole T, Stromskag K, Brenne A
Scand J Prim Health Care. 2024; 42(3):471-482.
PMID: 38662520
PMC: 11332305.
DOI: 10.1080/02813432.2024.2346131.
Digitally Enabled Transitional Care Management in Oncology.
Daly B, Cracchiolo J, Holland J, Ebstein A, Flynn J, Duck E
JCO Oncol Pract. 2024; 20(5):657-665.
PMID: 38382002
PMC: 11855599.
DOI: 10.1200/OP.23.00565.
Indicators of Clinical Trajectory in Patients With Cancer Who Receive Cardiopulmonary Resuscitation.
Chawla S, Gutierrez C, Rajendram P, Seier K, Tan K, Stoudt K
J Natl Compr Canc Netw. 2023; 21(1):51-59.e10.
PMID: 36634611
PMC: 10228640.
DOI: 10.6004/jnccn.2022.7072.
Budget impact analysis of providing hospital inpatient care at home virtually, starting with two specific surgical patient groups.
Peters G, Doggen C, van Harten W
BMJ Open. 2022; 12(8):e051833.
PMID: 35914920
PMC: 9345035.
DOI: 10.1136/bmjopen-2021-051833.
Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens.
Jensen C, Heiling H, Beke K, Deal A, Bryant A, Coombs L
Haematologica. 2022; 108(4):1006-1014.
PMID: 35861016
PMC: 10071106.
DOI: 10.3324/haematol.2022.280728.
Acute home-based care for patients with cancer to avoid, substitute, and follow emergency department visits: a conceptual framework using Porter's Five Forces.
Baugh C, Dorner S, Levine D, Handley N, Mooney K
Emerg Cancer Care. 2022; 1(1):8.
PMID: 35844665
PMC: 9247981.
DOI: 10.1186/s44201-022-00008-3.
Home-deliverable antitumoral treatments in the age of COVID-19: the Portsmouth experience and a narrative review.
Mechahougui H, Yusof H, Baudoux N, Acharige S, Friedlaender A
Mediastinum. 2022; 6:12.
PMID: 35832238
PMC: 9272088.
DOI: 10.21037/med-21-26.
Lessons for Oncology From the COVID-19 Pandemic: Operationalizing and Scaling Virtual Cancer Care in Health Systems.
Roberts T, Lennes I
Cancer J. 2022; 28(2):125-133.
PMID: 35333498
PMC: 9158540.
DOI: 10.1097/PPO.0000000000000579.
A research agenda for hospital at home.
Leff B, DeCherrie L, Montalto M, Levine D
J Am Geriatr Soc. 2022; 70(4):1060-1069.
PMID: 35211969
PMC: 9303641.
DOI: 10.1111/jgs.17715.
Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial.
Mooney K, Titchener K, Haaland B, Coombs L, ONeil B, Nelson R
J Clin Oncol. 2021; 39(23):2586-2593.
PMID: 33999660
PMC: 8478372.
DOI: 10.1200/JCO.20.03609.
Advances and unanswered questions in management of acute myeloid leukemia in older adults: A glimpse into the future.
Bhatt V
J Geriatr Oncol. 2021; 12(6):980-984.
PMID: 33602593
PMC: 8260436.
DOI: 10.1016/j.jgo.2021.02.011.
Creating and Validating a Predictive Model for Suitability of Hospital at Home for Patients With Solid-Tumor Malignancies.
Chen K, Desai K, Sureshanand S, Adelson K, Schwartz J, Gross C
JCO Oncol Pract. 2021; 17(4):e556-e563.
PMID: 33417488
PMC: 8257922.
DOI: 10.1200/OP.20.00663.
Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper.
Cooksley T, Font C, Scotte F, Escalante C, Johnson L, Anderson R
Support Care Cancer. 2020; 29(2):1129-1138.
PMID: 33230644
PMC: 7682766.
DOI: 10.1007/s00520-020-05906-y.
Treating Hematologic Malignancies During a Pandemic: Utilizing Telehealth and Digital Technology to Optimize Care.
Binder A, Handley N, Wilde L, Palmisiano N, Lopez A
Front Oncol. 2020; 10:1183.
PMID: 32676459
PMC: 7333768.
DOI: 10.3389/fonc.2020.01183.
Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Bange E, Doucette A, Gabriel P, Porterfield F, Harrigan J, Wang R
JCO Oncol Pract. 2020; 16(8):e678-e687.
PMID: 32130074
PMC: 7427417.
DOI: 10.1200/JOP.19.00328.
